RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.120
-0.030 (-2.61%)
At close: Aug 12, 2026, 4:00 PM EDT
1.220
+0.099 (8.88%)
After-hours: Aug 12, 2026, 5:12 PM EDT
RenovoRx Revenue
RenovoRx had revenue of $563.00K in the quarter ending March 31, 2026, with 185.79% growth. This brings the company's revenue in the last twelve months to $1.49M, up 520.42% year-over-year. In the year 2025, RenovoRx had annual revenue of $1.12M with 2,511.63% growth.
Revenue (ttm)
$1.49M
Revenue Growth
+520.42%
P/S Ratio
33.92
Revenue / Employee
$87,588
Employees
17
Market Cap
50.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.12M | 1.08M | 2,511.63% |
| Dec 31, 2024 | 43.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 64.09M |
| TScan Therapeutics | 7.11M |
| Immutep | 5.28M |
| Seres Therapeutics | 1.88M |
| Mereo BioPharma Group | 500.00K |
| aTyr Pharma | 190.00K |
| Impact BioMedical | 35.00K |
| eXoZymes | -700.00 |
RNXT News
- 1 hour ago - RenovoRx Earnings Call Transcript: Q2 2026 - Transcripts
- 1 hour ago - RenovoRx Earnings release: Q2 2026 - Filings
- 1 hour ago - RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth - GlobeNewsWire
- 1 day ago - RenovoRx completes enrollment in TIGeR-PaC trial - TheFly
- 1 day ago - RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 6 days ago - RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors - GlobeNewsWire
- 8 days ago - RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th - GlobeNewsWire
- 14 days ago - RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET - GlobeNewsWire